| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Eloxx Pharmaceuticals, Inc. Common Stock$12.21
-1.68 (-12.1%)
Market Cap
-
EPS
-
P/E Ratio
-
Value Trade
13.63 K
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
41.38 K
52 Week Range
-
% held by Insiders
58.1 %
% held by Institutions
-
Enterprise Value
-
Total Shares
3.92 M
Short %
0.27 %
Float Shares
3.07 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ELOX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
ELOX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ELOX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ELOX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ELOX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ELOX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-ELOX
Nov 13, 2023Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update Kidney morphology improved in all three patients with protein re-expression consistent with disease regression
Eloxx Pharmaceuticals reported its financial results for Q3 2023, demonstrating improved outcomes in its Phase 2 clinical trial for ELX-02, where kidney morphology showed enhancements in all treated patients. The company's financials reflected a reduced net loss of $3.6 million, down from $7.5 million in the same quarter last year. Additionally, Eloxx is progressing towards a strategic partnership for ZKN-013 while managing challenges related to its stock delisting from Nasdaq. With cash reserves of $4.8 million, they aim to support operations into 2024.
Read more →-ELOX
Aug 21, 2023RARE Thinking for RARE Solutions Small Molecule Gene Therapy August 2023 / 2 Forward-looking statements This presentation contains forward-looking statements, which are generally statements that are not historical facts.
The article discusses the promising results of ELX-02 in treating Autosomal Dominant Polycystic Kidney Disease (ADPKD) in organoid models and clinical trials. Data shows that ELX-02 can reduce cyst burden and improve disease outcomes, with a notable proteinuria remission rate observed in patients. The ongoing research and studies indicate a forward momentum towards pivotal trials, establishing the drug's potential in addressing PKD-related complications.
Read more →-ELOX
Jul 13, 2023Baseline characteristics of patients that have completed therapy Patient Age Sex COl4 Gene Affected Nonsense Mutation RAAS Block dose Cr (mg/dL) Proteinuria (mg/g) 4401 - 01 13 Male COL4A4 c.2906C G*; p.Ser969X Enalapr
The article presents preliminary results from a Phase 2 study on Alport syndrome patients undergoing treatment with Enalapril. Notably, patient 4401 - 02 experienced a significant reduction in proteinuria, achieving partial remission after eight weeks. However, the other two patients did not exhibit marked changes in their condition, indicating variability in treatment response. The findings suggest potential benefits of the therapy, while also highlighting the need for further investigation.
Read more →-ELOX
May 15, 2023Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update Topline results to include biopsy results for the Phase 2 clinical study evaluating ELX-02 for the potential t
Eloxx Pharmaceuticals has reported its financial results for Q1 2023, highlighting anticipated biopsy results for the Phase 2 study of ELX-02 aimed at treating Alport syndrome. The company received FDA clearance for a new clinical trial targeting recessive Dystrophic Epidermolysis Bullosa (RDEB). Financially, Eloxx posted a reduced net loss of $6.2 million, an improvement from the previous year's loss. However, the company's cash flow situation remains critical, necessitating careful management as it prepares for potential Phase 3 trials.
Read more →-ELOX
Apr 3, 2023Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update Three patients now dosed in Phase 2 clinical study evaluating ELX-02 for the treatment of Alport syndrome; en
Eloxx Pharmaceuticals reported its financial results for Q4 2022, indicating a net loss of $6.3 million. The company updated its business, highlighting that three patients have been dosed in a Phase 2 study of ELX-02 for Alport syndrome, with initial positive data regarding proteinuria reduction. Additionally, the Investigational New Drug application for ZKN-013 for recessive dystrophic epidermolysis bullosa was filed, aiming to expand its drug portfolio. Eloxx indicated a timeline for possible Phase 3 study activities later in 2023, contingent on successful results.
Read more →-ELOX
Dec 2, 2022Eloxx Pharmaceuticals Announces Reverse Stock Split Effective ELOX common stock expected to begin trading on a split-adjusted basis on
Eloxx Pharmaceuticals Announces Reverse Stock Split Effective ELOX common stock expected to begin trading on a split-adjusted basis on December 2, 2022 - December 1, 2022 - Eloxx Pharmaceuticals, Inc. (the "Company") (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic
Read more →-ELOX
Nov 10, 2022Eloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business Update Started proof-of-concept Phase 2 clinical trial with ELX-02 in up to eight Alport syndrome patients with nonse
Eloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business Update Started proof-of-concept Phase 2 clinical trial with ELX-02 in up to eight Alport syndrome patients with nonsense mutations; topline results expected in the first half
Read more →-ELOX
Sep 14, 2022Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients Combination of subcutaneous ELX-02 with ivacaftor did not achieve statistical signi
Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients Combination of subcutaneous ELX-02 with ivacaftor did not achieve statistical significance for efficacy endpoints in Phase 2 study in Class
Read more →-ELOX
Aug 15, 2022Eloxx Pharmaceuticals Reports Second Quarter 2022 Financial and Operating Results and Provides Business Update Topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor
Eloxx Pharmaceuticals Reports Second Quarter 2022 Financial and Operating Results and Provides Business Update Topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor expected by the end of the third quarter of 2022 On tra
Read more →-ELOX
Jul 5, 2022Eloxx Pharmaceuticals Announces Changes to Board of Directors Lindsay Androski, JD, MBA brings significant experience growing biotech companies through her roles as an executive at Roivant Social Ventures Gadi Veinrib, R
Eloxx Pharmaceuticals Announces Changes to Board Lindsay Androski, JD, MBA brings significant experience growing biotech companies through her roles as an executive at Roivant Social Ventures Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seeh
Read more →-ELOX
May 10, 2022Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update Cystic Fibrosis Foundation (CF Foundation) awarded up to $15.9 million for the ongoing ELX-02 clinical program
Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update Cystic Fibrosis Foundation (CF Foundation) awarded up to $15.9 million for the ongoing ELX-02 clinical program Topline data from cystic fibrosis (CF) Phase 2 expansi
Read more →-ELOX
Mar 31, 2022Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update
Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update Expect topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor by the end of the first half of 2022 Cystic Fibr
Read more →-ELOX
Nov 17, 2021Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients ELX-02 monotherapy dosed at 1.5mg/kg/day demonstrated a statistically s
tm2133239d1_ex99-1.htm Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients ELX-02 monotherapy dosed at 1.5mg/kg/day demonstrated a statistically significant 5.4mmol/L mean sweat c
Read more →-ELOX
Nov 9, 2021Eloxx Pharmaceuticals Reports Third Quarter 2021 Financial and Operating Results and Provides Business Update Data from Monotherapy Arms of Ongoing Phase 2 ELX-02 Cystic Fibrosis (CF) Clinical Trials Expected in Fourth Q
Eloxx Pharmaceuticals Reports Third Quarter 2021 Financial and Operating Results and Provides Business Update Data from Monotherapy Arms of Ongoing Phase 2 ELX-02 Cystic Fibrosis (CF) Clinical Trials Expected in Fourth Quarter of 2021 Received FDA Fast Track Designation for E
Read more →-ELOX
Aug 16, 2021Eloxx Pharmaceuticals Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update Added Additional Treatment Arm and Provided Enrollment Update for Ongoing ELX-02 Phase 2 Clinical Trials for
Pharmaceuticals Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update Added Additional Treatment Arm and Provided Enrollment Update for Ongoing ELX-02 Phase 2 Clinical Trials for Cystic Fibrosis (CF) Nominated ZKN-013 as Lead Candidate for Re
Read more →-ELOX
Jul 6, 2021Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis Data Readout for First Four Treatment Arms Expected in the Fourth Quarter of 2021 WATERTOWN, MA - JULY 6, 2021 - E
Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis for First Four Treatment Arms Expected in the Fourth Quarter of 2021 WATERTOWN, MA - JULY 6, 2021 - Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) today provided an update on
Read more →-ELOX
May 27, 2021Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents
Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents Leverages TURBO-ZM Synthetic Chemistry Platform for Designing Oral Macrolide-based Ribosome Modulating Agents (RMAs) Complements ELX-02 program in Phase
Read more →-ELOX
May 18, 2021Eloxx Pharmaceuticals, Inc. Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Eloxx Pharmaceuticals, Inc. Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares WALTHAM, Mass., May 18, 2021 (GLOBE NEWSWIRE) - Eloxx Pharmaceuticals, Inc. (the "Company") (Nasdaq: ELOX), a leader i
Read more →-ELOX
May 6, 2021Eloxx Pharmaceuticals Reports First Quarter 2021 Financial and Operating Results and Provides Business Update Acquisition of Zikani Therapeutics, Ribosomal Modulation Company; Combined Company Advancing Ribosomal RNA-Tar
Pharmaceuticals Reports First Quarter 2021 Financial and Operating Results and Provides Business Update Acquisition of Zikani Therapeutics, Ribosomal Modulation Company; Combined Company Advancing Ribosomal RNA-Targeted Genetic Therapies Additional Treatment Arm Added to Ongoi
Read more →-ELOX
Apr 29, 2021Eloxx Pharmaceuticals Adds Additional Treatment Arm to Ongoing Phase 2 Clinical Studies for Cystic Fibrosis Fifth Treatment Arm to Evaluate Safety of ELX-02 in Combination with Kalydeco (ivacaftor) Reaffirmed Data Readou
Eloxx Pharmaceuticals Adds Additional Treatment Arm to Ongoing Phase 2 Clinical Studies for Cystic Fibrosis Fifth Treatment Arm to Evaluate Safety of ELX-02 in Combination with Kalydeco (ivacaftor) Reaffirmed Data Readout for First Four Treatment Arms On Track for Second Hal
Read more →-ELOX
Apr 20, 2021RARE Thinking for RARE Solutions Creating a World Leader in Ribosome Targeted Genetic Therapies April 2021 / 2 Forward - looking statements This presentation contains forward - looking statements, which are generally sta
RARE Thinking for RARE Solutions Creating a World Leader in Ribosome Targeted Genetic Therapies April 2021 / 2 Forward - looking statements This presentation contains forward - looking statements, which are generally statements that are not historical facts . Forward - looking s
Read more →-ELOX
Apr 1, 2021Creating a Leader in Ribosomal RNA - Targeted Genetic Therapy Eloxx A cquires Zikani Therapeutics
Creating a Leader in Ribosomal RNA - Targeted Genetic Therapy Eloxx A cquires Zikani Therapeutics April 1, 2021 This presentation contains forward - looking statements, which are generally statements that are not historical facts . Forward - looking statements can be identified
Read more →-ELOX
Mar 11, 2021Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operating Results and Provides Business Update We expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first
Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operating Results and Provides Business Update We expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first half of this year We have expanded our global Phase 2
Read more →-ELOX
Jan 13, 2021Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation (CF Foundation) To Provide Increased Funding and Support for ELX-02 Global Phase 2 Clinical Trial Program The CF Foundation's partial funding of the U.S. trial h
Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation (CF Foundation) To Provide Increased Funding and Support for ELX-02 Global Phase 2 Clinical The CF Foundation's partial funding of the U.S. trial has been extended to partial funding of the global clinical trial progra
Read more →-ELOX
Nov 5, 2020Eloxx Pharmaceuticals Reports Third Quarter 2020 Financial and Operating Results and Provides Business Update Expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first half of 2021 The
Eloxx Pharmaceuticals Reports Third Quarter 2020 Financial and Operating Results and Provides Business Update Expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first half of 2021 The independent Safety Review Committees for our Phase 2 cy
Read more →-ELOX
Aug 12, 2020Enrollment in the U.S. Phase 2 Clinical Trial in Cystic Fibrosis Has Resumed After Being Paused in Response to the COVID-19 Pandemic Waltham, MA.
Enrollment in the U.S. Phase 2 Clinical Trial in Cystic Fibrosis Has Resumed After Being Paused in Response to the COVID-19 Pandemic Waltham, MA. - August 12, 2020 - Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discov
Read more →-ELOX
Aug 6, 2020Eloxx Pharmaceuticals Reports Second Quarter 2020 Financial and Operating Results and Provides Business Update Enrollment in our Phase 2 clinical trial program for ELX-02 in cystic fibrosis has been resumed in Europe and
Eloxx Pharmaceuticals Reports Second Quarter 2020 Financial and Operating Results and Provides Business Update Enrollment in our Phase 2 clinical trial program for ELX-02 in cystic fibrosis has been resumed in Europe and Israel after being temporarily paused due to the COVID
Read more →-ELOX
Aug 4, 2020Eloxx Pharmaceuticals Receives U.S. Orphan Drug Designation for ELX-02 for the Treatment of Cystic Fibrosis ELX-02 had previously been granted orphan medicinal product designation for the treatment of Cystic Fibrosis by
Eloxx Pharmaceuticals Receives U.S. Orphan Drug Designation for ELX-02 for the Treatment of Cystic Fibrosis ELX-02 had previously been granted orphan medicinal product designation for the treatment of Cystic Fibrosis by the European Medicines Agency Waltham, MA. - August 04,
Read more →-ELOX
Jun 17, 2020Enrollment in Phase 2 Clinical Trial in Cystic Fibrosis Has Been Resumed in Israel and Europe After Being Paused Temporarily in Response to the COVID-19 Pandemic Waltham, MA.
in Phase 2 Clinical Trial in Cystic Fibrosis Has Been Resumed in Israel and Europe After Being Paused Temporarily in Response to the COVID-19 Pandemic 17, 2020 - Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery a
Read more →-ELOX
May 7, 2020Eloxx Pharmaceuticals Reports First Quarter 2020 Financial and Operating Results and Provides Business Update Completing our Phase 2 clinical trial program for ELX-02 in Cystic Fibrosis remains our highest priority Precl
Pharmaceuticals Reports First Quarter 2020 Financial and Operating Results and Provides Business Update our Phase 2 clinical trial program for ELX-02 in Cystic Fibrosis remains our highest priority studies advancing in autosomal dominant polycystic kidney disease (ADPKD) and in
Read more →-ELOX
Mar 25, 2020Eloxx Pharmaceuticals Provides Update on the Impact of Novel Coronavirus (COVID-19) on Phase 2 Clinical Trials in Cystic Fibrosis Enrollment in our Phase 2 Cystic Fibrosis Trials has been paused temporarily in response t
Eloxx Pharmaceuticals Provides Update on the Impact of Novel Coronavirus (COVID-19) on Phase 2 Clinical Trials in Cystic Fibrosis Enrollment in our Phase 2 Cystic Fibrosis Trials has been paused temporarily in response to the COVID-19 pandemic Cystic Fibrosis patients, espec
Read more →-ELOX
Mar 5, 2020Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial and Operating Results and Provides Business Update Topline data from Phase 2 Cystic Fibrosis clinical trials for ELX-02 in H1 2020 Realignment str
Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial and Operating Results and Provides Business Update Topline data from Phase 2 Cystic Fibrosis clinical trials for ELX-02 in H1 2020 Realignment strengthens commitment to Cystic Fibrosis and strategic fl
Read more →-ELOX
Feb 26, 2020Eloxx Strengthens its Commitment to Cystic Fibrosis Through Reallocating Resources Reiterate topline data from Phase 2 Cystic Fibrosis clinical trials for ELX-02 expected in H1 2020 Results from clinical and preclinical
Eloxx Strengthens its Commitment to Cystic Fibrosis Through Reallocating Resources Reiterate topline data from Phase 2 Cystic Fibrosis clinical trials for ELX-02 expected in H1 2020 Results from clinical and preclinical research to date support Company's prioritization of Cy
Read more →-ELOX
Jan 14, 2020Eloxx Pharmaceuticals Provides Update on Progress of Its Phase 2 Clinical Programs for ELX-02 and ERSG Pipeline at Biotech Showcase Ô Phase 2 cystic fibrosis program for ELX-02 expected to be fully enrolled in the
Pharmaceuticals Provides Update on Progress of Its Phase 2 Clinical Programs for ELX-02 and ERSG Pipeline at Biotech Showcase 2 cystic fibrosis program for ELX-02 expected to be fully enrolled in the first quarter of 2020 and topline results expected during the first half of 20
Read more →-ELOX
Nov 5, 2019Eloxx Pharmaceuticals Reports Third Quarter 2019 Financial and Operating Results and Provides Business Update - Presented Positive Phase 1 Data from SAD and MAD Studies at North American Cystic Fibrosis Conference -On tr
Eloxx Pharmaceuticals Reports Third Quarter 2019 Financial and Operating Results and Provides Business Update -Presented Positive Phase 1 Data from SAD and MAD Studies at North American Cystic Fibrosis Conference -On track to report top line Phase 2 data in nephropathic cyst
Read more →-ELOX
Aug 7, 2019Eloxx Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results and Provides Business Update Phase 2 cystic fibrosis clinical trial IND is open in the U.S., protocol endorsed by the Cystic Fibrosis Foun
Eloxx Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results and Provides Business Update Phase 2 cystic fibrosis clinical trial IND is open in the U.S., protocol endorsed by the Cystic Fibrosis Foundation (CFF) Initiated a Phase 2 clinical trial for ELX
Read more →-ELOX
Aug 7, 2019Eloxx Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial for ELX-02 in Cystinosis Dr. Paul Goodyer, Professor of Pediatrics at McGill University and recognized leader in hereditary renal disease, is the princ
Eloxx Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial for ELX-02 in Cystinosis Dr. Paul Goodyer, Professor of Pediatrics at McGill University and recognized leader in hereditary renal disease, is the principal investigator in the Phase 2 clinical trial On track
Read more →-ELOX
Jul 31, 2019Eloxx Pharmaceuticals Announces Open Investigational New Drug Application (IND) for a Phase 2 Clinical Trial of ELX-02 in Cystic Fibrosis Patients with the G542X Mutation in the US and Protocol Endorsement from the Cysti
Eloxx Pharmaceuticals Announces Open Investigational New Drug Application (IND) for a Phase 2 Clinical Trial of ELX-02 in Cystic Fibrosis Patients with the G542X Mutation in the US and Protocol Endorsement from the Cystic Fibrosis Foundation (CFF) On track to report top line
Read more →-ELOX
Jun 24, 2019Eloxx Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares Waltham, MA.
Eloxx Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares Waltham, MA. - June 24, 2019- Eloxx Pharmaceuticals, Inc. ("Eloxx") (Nasdaq: ELOX) today announced the closing of its underwritt
Read more →-ELOX
Jun 19, 2019Eloxx Pharmaceuticals Announces Proposed Public Offering of Common Stock Waltham, MA.
Eloxx Pharmaceuticals Announces Proposed Public Offering of Common Stock Waltham, MA. - June 19, 2019- Eloxx Pharmaceuticals, Inc. ("Eloxx") (Nasdaq: ELOX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering, subject
Read more →-ELOX
May 2, 2019Eloxx Pharmaceuticals Reports First Quarter 2019 Financial and Operating Results and Provides Business Update Positive new preclinical data for Eloxx ERSG molecules presented at the Association for Research in Vision and
Eloxx Pharmaceuticals Reports First Quarter 2019 Financial and Operating Results and Provides Business Update Positive new preclinical data for Eloxx ERSG molecules presented at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting May 2, 2019 de
Read more →-ELOX
Mar 8, 2019Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial and Operating Results and Provides Business Update Eloxx announces the hiring of Dr. Susan Schneider as SVP Ophthalmology to lead the development
Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial and Operating Results and Provides Business Update Eloxx announces the hiring of Dr. Susan Schneider as SVP Ophthalmology to lead the development of its rare inherited retinal disease programs Abstract
Read more →-ELOX
Nov 8, 2018Eloxx Pharmaceuticals Reports Third Quarter 2018 Financial and Operating Results and Provides Business Update ELX-02 has been granted an orphan drug designation by the European Medicines Agency (EMA) for Cystic Fibrosis
Eloxx Pharmaceuticals Reports Third Quarter 2018 Financial and Operating Results and Provides Business Update ELX-02 has been granted an orphan drug designation by the European Medicines Agency (EMA) for Cystic Fibrosis Advancing several investigational drug candidates from
Read more →-ELOX
Oct 2, 2018Unlocking protein production with translational read - through for rare genetic diseases Cantor Global Healthcare
Unlocking protein production with translational read - through for rare genetic diseases Cantor Global Healthcare, October 2, 2018 This press release contains forward - looking statements, which are generally statements that are not historical facts. Forward - looking statements
Read more →-ELOX
Aug 7, 2018Eloxx Pharmaceuticals Reports Second Quarter 2018 Financial and Operating Results and Provides Business Update CTA approved in Belgium and IND open in the U.S. for investigational drug candidate, ELX-02 On track to initi
Eloxx Pharmaceuticals Reports Second Quarter 2018 Financial and Operating Results and Provides Business Update CTA approved in Belgium and IND open in the U.S. for investigational drug candidate, ELX-02 On track to initiate Phase 2 clinical trials in cystic fibrosis and cyst
Read more →-ELOX
Jun 25, 2018Eloxx Expands Leadership Team with Two Global Pharmaceutical Executives to Accelerate Growth Dr. Greg Williams appointed Chief Operating Officer David P. Snow appointed Chief Business Officer Eloxx added to the Russell 2
Eloxx Expands Leadership Team with Two Global Pharmaceutical Executives to Accelerate Growth Dr. Greg Williams appointed Chief Operating Officer David P. Snow appointed Chief Business Officer Eloxx added to the Russell 2000 Index effective June 25, 2018 Waltham, MA, June 25,
Read more →-ELOX
May 10, 2018Eloxx Pharmaceuticals Reports First Quarter 2018 Financial and Operating Results and Provides Business Update Company on track to initiate Phase 2 clinical trials for investigational drug ELX-02 in cystic fibrosis and cy
Eloxx Pharmaceuticals Reports First Quarter 2018 Financial and Operating Results and Provides Business Company on track to initiate Phase 2 clinical trials for investigational drug ELX-02 in cystic fibrosis and cystinosis in 2018 and sufficiently funded to top line data Format
Read more →-ELOX
Apr 24, 2018Eloxx Pharmaceuticals Announces Proposed Public Offering of Common Stock Waltham, MA .
Eloxx Pharmaceuticals Announces Proposed Public Offering of Common Stock Waltham, MA. April 24, 2018 Eloxx Pharmaceuticals, Inc. ( Eloxx ) (OTCQB: ELOX) today announced that it intends to offer and sell, subject to market and other conditions, 5,000,000 shares of its common st
Read more →-ELOX
Mar 20, 2018Eloxx Pharmaceuticals Reports Full Year 2017 Financial and Operating Results and Provides Business Update Company to host webcast and conference call on Tuesday
Eloxx Pharmaceuticals Reports Full Year 2017 Financial and Operating Results and Provides Business Update Company to host webcast and conference call on Tuesday, March 20, 2018 at 8 am ET Management to discuss recent data and progress on development plans Waltham, MA. March 19
Read more →-ELOX
Feb 28, 2018Eloxx Pharmaceuticals Appoints Biotech Leader, Dr. Jasbir Seehra, Co-founder of Acceleron Pharma, to Board of Directors
Eloxx Pharmaceuticals Appoints Biotech Leader, Dr. Jasbir Seehra, Acceleron Pharma, to Board of Directors WALTHAM, Mass., February 28, 2018 (GLOBE NEWSWIRE) Eloxx Pharmaceuticals, Inc. ( Eloxx ), (ELOX) (Other OTC:SVOND) a clinical-stage biopharmaceutical company developing no
Read more →-ELOX
Dec 27, 2017Eloxx Pharmaceuticals Appoints Robert Ward Chairman and Chief Executive Officer Biopharmaceutical Industry Leader with Extensive Experience In Drug Development, Strategic Business Combinations and Commercialization to Le
Eloxx Pharmaceuticals Appoints Robert Ward Chairman and Chief Executive Officer Biopharmaceutical Industry Leader with Extensive Experience In Drug Development, Strategic Business Combinations and Commercialization to Lead The Company's Strategy, Vision and Execution MA - De
Read more →-ELOX
Dec 19, 2017Sevion Therapeutics Announces 1-for-20 Reverse Stock Split San Diego, CA
Sevion Therapeutics Announces 1-for-20 Reverse San Diego, CA - December 19, 2017 - Sevion Therapeutics, Inc. (OTCQB: SVON) ("Sevion") today announced that the Board approved a 1-for-20 reverse stock split, to be effective 4:00 p.m. on Tuesday, December 19, 2017. The Company's
Read more →-ELOX
Aug 2, 2017Eloxx Pharmaceuticals Secures US$8 Million Investment from LSP, Increasing Total Raised in Series C to US$38 million Financing to support advancement of novel disease-modifying therapy targeting genetic diseases, includi
Eloxx Pharmaceuticals Secures US$8 Million Investment from LSP, Increasing Total Raised in Series C to US$38 million Financing to support advancement of novel disease-modifying therapy targeting genetic diseases, including cystic fibrosis SAN DIEGO and REHOVOT, Israel, Aug.
Read more →-ELOX
Jun 26, 2017ELOXX PHARMACUETICALS RECEIVES A US$6 MILLION INVESTMENT FROM KIP and DCS TO ADVANCE A NOVEL DISEASE-MODIFYING THERAPY TARGETING GENETIC DISEASES INCUDING CYSTIC FIBROSIS San Diego, CA Rehovot, Israel & Seoul , South Kor
ELOXX PHARMACUETICALS RECEIVES A US$6 MILLION INVESTMENT FROM KIP and DCS TO ADVANCE A NOVEL DISEASE-MODIFYING THERAPY TARGETING GENETIC DISEASES INCUDING CYSTIC FIBROSIS San Diego, CA Rehovot, Israel & Seoul, South Korea - June 26, 2017 - Today, Korea Investment Partners (KIP
Read more →-ELOX
Jun 2, 2017Sevion Therapeutics Inc. and Eloxx Pharmaceuticals Ltd Announce the Entering into of an Acquisition Transaction Combined company to advance Eloxx first in class compounds targeting genetic diseases caused by non-sense mu
Therapeutics Inc. and Eloxx Pharmaceuticals Ltd Announce the Entering into of an Acquisition Transaction company to advance Eloxx first in class compounds targeting genetic diseases caused by non-sense mutations Diego, CA and Rehovot, Israel - June 2, 2017 - Sevion Therapeutics
Read more →-ELOX
Nov 17, 2015Sevion Therapeutics Reports First Quarter 2016 Financial Results
Therapeutics Reports First Quarter 2016 Financial Results SAN DIEGO, CA - November 17, 2015 - Sevion Therapeutics, Inc. ("Sevion" or the "Company")(OTCQB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of c
Read more →-ELOX
Oct 14, 2015Sevion Therapeutics Reports Fiscal Year 2015 Financial Results San Diego, CA
Sevion Therapeutics Reports Fiscal Year 2015 Financial Results San Diego, CA - October 14, 2015 - Sevion Therapeutics, Inc. ("Sevion" or the "Company") (OTCQB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatmen
Read more →-ELOX
Jun 16, 2015Sevion Therapeutics Announces Immuno Oncology Discovery Program at
Sevion Therapeutics Announces Immuno Oncology Discovery Program at BIO SAN DIEGO, CA - June 16, 2015 - Sevion Therapeutics, Inc. ("Sevion" or the "Company") (OTCQB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the tre
Read more →-ELOX
May 15, 2015Sevion Therapeutics Reports Third Quarter 2015 Financial Results San Diego, CA
Sevion Therapeutics Reports Third Quarter 2015 Financial Results San Diego, CA - May 15, 2015 - Sevion Therapeutics, Inc. ("Sevion" or the "Company") (OTCQB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment
Read more →-ELOX
Feb 19, 2015Sevion Therapeutics Reports Second Quarter 2015 Financial Results San Diego, CA
Sevion Therapeutics Reports Second Quarter 2015 Financial Results San Diego, CA - February 18, 2014 - Sevion Therapeutics, Inc. ("Sevion" or the "Company") (OTCQB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the trea
Read more →-ELOX
Dec 22, 2014Sevion Announces Antibody Discovery Collaboration with Johnson & Johnson Innovation and Janssen San Diego, CA
Sevion Announces Antibody Discovery Collaboration with Johnson & Johnson Innovation and Janssen San Diego, CA - December 22, 2014 - Sevion Therapeutics Inc. ("Sevion" or the "Company") (OTCQB: SVON), a biopharmaceutical company which discovers, develops and acquires next-gene
Read more →-ELOX
Dec 8, 2014Sevion Therapeutics Presents Results of SNS01-T Phase 1b/2a Dose Escalation Study at ASH Annual Meeting
Sevion Therapeutics Presents Results of SNS01-T Phase 1b/2a Dose Escalation Study at ASH Annual Meeting SAN DIEGO, CA - December 8, 2014 - Sevion Therapeutics (OTCQB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the t
Read more →-ELOX
Nov 17, 2014Sevion Therapeutics Reports First Quarter 2015 Financial Results Bridgewater, NJ
Sevion Therapeutics Reports First Quarter 2015 Financial Results Bridgewater, NJ - November 17, 2014 - Sevion Therapeutics, Inc. ("Sevion" or the "Company") (OTCQB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the tre
Read more →-ELOX
Oct 3, 2014Sevion Therapeutics Announces New Ticker Symbol "SVON" BRIDGEWATER, N.J. (October 3 rd , 2014) - Sevion Therapeutics (OTCQB: SVON), a clinical stage company which discovers, develops and acquires next-generation biologic
Sevion Therapeutics Announces New Ticker BRIDGEWATER, N.J. (October 3rd, 2014) - Sevion Therapeutics (OTCQB: SVON), a clinical stage company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, announced today
Read more →-ELOX
Sep 29, 2014Sevion Therapeutics Reports Fiscal Year 2014 Financial Results BRIDGEWATER, N.J. (
Sevion Therapeutics Reports Fiscal Year 2014 Financial Results BRIDGEWATER, N.J. (September 29, 2014) - Senesco Technologies, Inc. doing business as Sevion Therapeutics ("Sevion" or the "Company") (OTCQB: SNTI) today reported financial results for the fiscal year ended June 3
Read more →-ELOX
Aug 29, 2014Senesco Closes Enrollment in Its Phase 1b/2a SNS01-T Study Bridgewater, N.J. (
Senesco Closes Enrollment in Its Phase Bridgewater, N.J. (August 29, 2014) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTCQB: SNTI) today announced the closing of enrollment in its ongoing Phase 1b/2a open-label, multiple-dose, dose-escalation clinical trial of
Read more →-ELOX
Jun 27, 2014Senesco Technologies, Inc. Corporate Overview OTC QB: SNTI BIO San Diego June, 2014 1 Certain statements included in this press release are forward - looking statements within the meaning of the Private Securities Litiga
Senesco Technologies, Inc. Corporate Overview OTC QB: SNTI BIO San Diego June, 2014 1 Certain statements included in this press release are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materi
Read more →-ELOX
May 19, 2014Senesco Completes Acquisition of Fabrus Bridgewater, NJ - (
Completes Acquisition of Fabrus - (May 19, 2014) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTCQB: SNTI), completed its acquisition of Fabrus, Inc. ("Fabrus"), a biotechnology company focused on expanding the clinical impact of antibodies by addressing drug tar
Read more →-ELOX
May 9, 2014Senesco Technologies Reports Second Quarter of Fiscal Year 2014 Financial Results BRIDGEWATER, N.J. (
Senesco Technologies Reports Second Quarter of Fiscal Year 2014 Financial Results BRIDGEWATER, N.J. (May 9, 2014) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTCQB: SNTI) today announced financial results for the three months ended March 31, 2014 ("Third Quarte
Read more →-ELOX
Apr 28, 2014Senesco Announces Presentation on the Effectiveness of eIF5A in Inhibiting Tumor Progression in Liver Cancer Models Presentation at 17 th Annual Meeting of American Society of Gene & Cell Therapy BRIDGEWATER, N.J. (
Senesco Announces Presentation on the Effectiveness of eIF5A in Inhibiting Tumor Progression in Liver Cancer Models Presentation at 17th Annual Meeting of American Society of Gene & Cell Therapy BRIDGEWATER, N.J. (April 28, 2014) - Senesco Technologies, Inc. ("Senesco" or th
Read more →-ELOX
Mar 12, 2014Senesco Opens Two New Clinical Trial Sites and Initiates Treatment of the First Patient in South Africa BRIDGEWATER, N.J. (March 12 th , 2014) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTC QB: SNTI) repo
Senesco Opens Two New Clinical Trial Initiates Treatment of the First Patient BRIDGEWATER, N.J. (March 12th, 2014) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTC QB: SNTI) reported the opening of two new sites in the Republic of South Africa at Pretoria East H
Read more →-ELOX
Mar 4, 2014In Non-clinical Cancer Studies Senesco's Therapeutic Candidate, SNS01-T, Works Synergistically in Combination with the Active Components of Revlimid and Velcade Studies Provide Additional Confirmation That SNS01-T Prefer
Cancer Studies Senesco's Therapeutic Candidate, SNS01-T, Works Synergistically in Combination with the Active Components of Revlimid and Velcade Provide Additional Confirmation That SNS01-T Preferentially Targets Cancer Cells Bridgewater, N.J. (March 4th, 2014) Senesco Techn
Read more →-ELOX
Feb 11, 2014Senesco Technologies, Inc. Changing Cancer Therapy Annual Meeting 2014
Senesco Technologies, Inc. Changing Cancer Therapy Annual Meeting 2014 February 11, 2014 Certain statements included in this presentation are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . Actual results could differ mat
Read more →-ELOX
Jan 9, 2014First Patient in Cohort 4 Receives Infusion of Senesco's Therapeutic Candidate, SNS01-T, For the Treatment of Multiple Myeloma and Non-Hodgkins Lymphoma in Phase 1b/2a Clinical Trial BRIDGEWATER, N.J. (January 9 th , 201
First Patient in Cohort 4 Receives Infusion of Senesco's Therapeutic Candidate, SNS01-T, For the Treatment of Multiple Myeloma and Non-Hodgkins Lymphoma in BRIDGEWATER, N.J. (January 9th, 2014) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTC QB: SNTI) reported
Read more →-ELOX
Dec 30, 2013Senesco Announces Letter of Intent to Merge with Fabrus Phil Frost, Investor in Senesco and Fabrus, comments on Merger Plans Bridgewater, NJ - (
Senesco Announces Letter of Intent to Phil Frost, Investor in Senesco and Fabrus, comments on Merger Plans - (December 30, 2013) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTCQB: SNTI), today announced that it has agreed to terms and executed a non-binding Le
Read more →-ELOX
Dec 12, 2013Senesco Announces up to $25.2 Million Equity Financing BRIDGEWATER, N.J. (
Senesco Announces up to $25.2 Million BRIDGEWATER, N.J. (December 12, 2013) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTCQB: SNTI) announced today that it has entered into a securities purchase agreement with certain investors to raise up to $25.2 million in g
Read more →-ELOX
Dec 10, 2013Senesco's Drug Candidate SNS01-T Selectively Kills Cancer Cells and Not Healthy Cells in Disease Models BRIDGEWATER, N.J. (
Senesco's Drug Candidate SNS01-T Selectively Kills Cancer Cells and Not Healthy Cells in Disease Models BRIDGEWATER, N.J. (December 10, 2013) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTC QB: SNTI) reported results of preclinical studies with SNS01-T at the 5
Read more →-ELOX
Dec 9, 2013Senesco Announces Results of Cohort 3 in SNS01-T Phase 1b/2a Trial More Robust Effects Observed BRIDGEWATER, N.J. (
Senesco Announces Results of Cohort 3 in SNS01-T Phase 1b/2a Trial More Robust Effects Observed BRIDGEWATER, N.J. (December 9, 2013) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTC QB: SNTI) reported results of cohort 3 in its Phase 1b/2a clinical study of SNS
Read more →-ELOX
Dec 4, 2013Completion of Cohort 3 in Phase 1b/2a Study in Multiple Myeloma and Non-Hodgkins B-Cell Lymphoma Data Review Committee Approves Dose Escalation to Cohort 4 BRIDGEWATER, N.J. (
Completion of Cohort 3 in Phase 1b/2a Study in Multiple Myeloma and Non-Hodgkins B-Cell Lymphoma Data Review Committee Approves Dose Escalation BRIDGEWATER, N.J. (December 4, 2013) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTC QB: SNTI) reported today the com
Read more →-ELOX
Nov 15, 2013Senesco Technologies Reports First Quarter of Fiscal Year 2014 Financial Results BRIDGEWATER, N.J. (
Senesco Technologies Reports First Quarter of Fiscal Year 2014 Financial Results BRIDGEWATER, N.J. (November 15, 2013) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTCQB: SNTID) today announced financial results for the three months ended September 30, 2013 ("Fi
Read more →-ELOX
Oct 24, 2013Senesco Opens New Clinical Trial Site
Senesco Opens New Clinical Trial Site Alliance and is Treating the First West Coast Patient BRIDGEWATER, N.J. (October 23, 2013) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTC QB: SNTID) reported the treatment of the first patient at the Company's newly opened
Read more →-ELOX
Oct 18, 2013Senesco Announces Reverse Stock Split BRIDGEWATER, N.J. (
Senesco Announces Reverse Stock Split BRIDGEWATER, N.J. (October 18, 2013) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTCQB: SNTI) today announced a 1-for-100 reverse split of its issued and outstanding shares of common stock. Trading will begin on a post-split
Read more →-ELOX
Oct 1, 2013Senesco Announces $1.725 Million Equity Financing BRIDGEWATER, N.J. (
Senesco Announces $1.725 Million Equity BRIDGEWATER, N.J. (October 1, 2013) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTCQB: SNTI) announced today that it has entered into a securities purchase agreement with certain investors to raise $1.725 million in gross
Read more →-ELOX
Sep 12, 2013Senesco Technologies Reports Fiscal Year 2013 Financial Results BRIDGEWATER, N.J. (
Senesco Technologies Reports Fiscal Year 2013 Financial Results BRIDGEWATER, N.J. (September 12, 2013) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTCQB: SNTI) today announced financial results for the 12 months ended June 30, 2013 ("Fiscal 2013"). Fiscal Four
Read more →-ELOX
Jun 19, 2013Senesco Announces Results of Cohort 2 of its SNS01-T Phase 1b/2a Trial BRIDGEWATER, N.J. (June 19 th , 2013) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTC QB: SNTI) reported results of cohort 2 in its Ph
Senesco Announces Results of Cohort 2 of its SNS01-T Phase 1b/2a Trial BRIDGEWATER, N.J. (June 19th, 2013) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTC QB: SNTI) reported results of cohort 2 in its Phase 1b/2a clinical study of SNS01-T. In cohort 2, the req
Read more →-ELOX
May 16, 2013Senesco Technologies Reports Second Quarter Fiscal 2013 Financial Results BRIDGEWATER, N.J. (May 16 th , 2013) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTCQB: SNTI) today reported financial results for
Senesco Technologies Reports Second Quarter Fiscal 2013 Financial Results N.J. (May 16th, 2013) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTCQB: SNTI) today reported financial results for the third quarter of fiscal year 2013 which ended on March 31, 2013. H
Read more →-ELOX
May 9, 2013Senesco Announces $1.255 Million Equity Financing BRIDGEWATER, N.J. (
Senesco Announces $1.255 Million Equity BRIDGEWATER, N.J. (May 9, 2013) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTCQB: SNTI) announced today that it has entered into a securities purchase agreement with certain institutional investors to raise $1.255 million
Read more →-ELOX
May 6, 2013Senesco Announces Start of Cohort 3 in Phase 1b/2a Study in Multiple Myeloma and Non-Hodgkins B-Cell Lymphoma Data Review Committee Approves Dose Escalation BRIDGEWATER, N.J. (May 6 th , 2013) - Senesco Technologies, Inc
Senesco Announces Start of Cohort 3 in Phase 1b/2a Study in Multiple Myeloma and Non-Hodgkins B-Cell Lymphoma Data Review Committee Approves Dose Escalation BRIDGEWATER, N.J. (May 6th, 2013) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTC QB: SNTI) reported to
Read more →-ELOX
Apr 22, 2013Senesco Announces Completion of Cohort 2 of its Phase 1b/2a Trial BRIDGEWATER, N.J. (April 22 nd , 2013) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTC QB: SNTI) reported today that it has completed cohor
Senesco Announces Completion of Cohort 2 of its Phase 1b/2a Trial BRIDGEWATER, N.J. (April 22nd, 2013) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTC QB: SNTI) reported today that it has completed cohort 2 in its Phase 1b/2a clinical study of SNS01-T. In coho
Read more →-ELOX
Apr 1, 2013Senesco Technologies, Inc.
Senesco Technologies, Inc. Helping to Cure Cancer and Feed the World Annual Meeting March 28 th , 2013 Certain statements included in this presentation are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . Actual results co
Read more →-ELOX
Feb 15, 2013Senesco Technologies Reports Second Quarter Fiscal 2013 Financial Results BRIDGEWATER, N.J. (February 15 th , 2013) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTCQB: SNTI) today reported financial results
Senesco Technologies Reports Second Quarter Fiscal 2013 Financial Results N.J. (February 15th, 2013) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTCQB: SNTI) today reported financial results for the second quarter of fiscal year 2013 which ended on December 31,
Read more →-ELOX
Jan 4, 2013Senesco Announces $3.0 Million Equity Financing BRIDGEWATER, N.J. (
Senesco Announces $3.0 Million Equity BRIDGEWATER, N.J. (January 4, 2013) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTCQB: SNTI) announced today that it has entered into a securities purchase agreement to raise approximately $3.0 million in gross proceeds thr
Read more →-ELOX
Dec 10, 2012Senesco Provides Summary of SNS01-T Progress in Phase 1b/2a Trial Interim Results presented at ASH BRIDGEWATER, N.J. (December 10 th , 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTC QB: SNTI) report
Senesco Provides Summary of SNS01-T Progress in Phase 1b/2a Trial Interim Results presented at ASH BRIDGEWATER, N.J. (December 10th, 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTC QB: SNTI) reported today that interim results from the on-going Phase 1b/
Read more →-ELOX
Nov 26, 2012Senesco Technologies Provides Corporate Update BRIDGEWATER, N.J. (
Senesco Technologies Provides Corporate BRIDGEWATER, N.J. (November 26, 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTC QB: SNTI) provided an update on Company November 21, 2012, Senesco announced that the Company's common stock is being quoted on the OTC.
Read more →-ELOX
Nov 21, 2012Senesco Announces Quotation of Common Stock on the Over-the-Counter Securities Market BRIDGEWATER, N.J. (November 21 st , 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTC:SNTI) announced that as of We
Senesco Announces Quotation of Common Stock on the Over-the-Counter Securities Market BRIDGEWATER, N.J. (November 21st, 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (OTC:SNTI) announced that as of Wednesday, November 21, 2012, the Company's common stock wil
Read more →-ELOX
Nov 21, 2012Senesco Announces Delisting of Common Stock from NYSE MKT LLC and Pending Transfer to an Over-the-Counter Securities Market BRIDGEWATER, N.J. (November 19 th , 2012) - Senesco Technologies, Inc. ("Senesco" or the "Compan
Senesco Announces Delisting of Common Stock from NYSE MKT LLC and Pending Transfer to an Over-the-Counter Securities Market BRIDGEWATER, N.J. (November 19th, 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE MKT: SNT) received verbal notice from NYSE MKT
Read more →-ELOX
Nov 15, 2012Senesco Technologies Reports First Quarter Fiscal 2013 Financial Results BRIDGEWATER, N.J. (November 15 th , 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE MKT: SNT) today reported financial result
Senesco Technologies Reports First Quarter Fiscal 2013 Financial Results N.J. (November 15th, 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE MKT: SNT) today reported financial results for the first quarter of fiscal year 2013 which ended on September 30
Read more →-ELOX
Nov 7, 2012Senesco Announces Expansion of Phase 1b/2a Study to Include Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma First DLBCL Patient Dosed in Study BRIDGEWATER, N.J. (November 7 th , 2012) - Senesco Technologies, Inc.
Senesco Announces Expansion of Phase 1b/2a Study to Include Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma First DLBCL Patient Dosed in Study BRIDGEWATER, N.J. (November 7th, 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE MKT: SNT) reported toda
Read more →-ELOX
Sep 18, 2012Senesco Technologies Reports Fiscal Year 2012 Financial Results BRIDGEWATER, N.J. (
Senesco Technologies Reports Fiscal Year 2012 Financial Results BRIDGEWATER, N.J. (September 18, 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE MKT: SNT) today announced financial results for the 12 months ended June 30, 2012 ("Fiscal 2012"). Fiscal Fo
Read more →-ELOX
Sep 13, 2012Senesco Announces First Dose of SNS01-T
Senesco Announces First Dose of SNS01-T in Cohort 2 of Phase 1b/2a Study in Multiple Myeloma Trial BRIDGEWATER, N.J. (September 13th, 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE MKT: SNT) reported today that the first patient has been enrolled and do
Read more →-ELOX
Sep 10, 2012Combining SNS01-T with Bortezomib Significantly Increases Its Effectiveness in Model of Multiple Myeloma BRIDGEWATER, N.J. (September 10 th , 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE MKT: SNT
SNS01-T with Bortezomib Significantly Increases Its in Model of Multiple Myeloma N.J. (September 10th, 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE MKT: SNT) announced today that the combination of bortezomib (the active component of VELCADE marketed
Read more →-ELOX
Aug 22, 2012SENESCO TECHNOLOGIES RECEIVES NOTICE OF NON-COMPLIANCE FROM NYSE MKT BRIDGEWATER, N.J. (August 27 th , 2012) - On
SENESCO TECHNOLOGIES RECEIVES NOTICE OF NON-COMPLIANCE FROM NYSE MKT BRIDGEWATER, N.J. (August 27th, 2012) - On August 22, 2012, Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE MKT: SNT) received a notice from NYSE Regulation, Inc. on behalf of NYSE MKT LLC (the
Read more →-ELOX
Aug 15, 2012Highly Statistically Significant Tumor Growth Inhibition by a Combination of Lenalidomide and SNS01-T in Cancer Model No Tumor Regrowth 8 Weeks after End of Treatment BRIDGEWATER, N.J. (August 13 th , 2012) - Senesco Tec
Highly Statistically Significant Tumor Growth Inhibition by a Combination of Lenalidomide and SNS01-T No Tumor Regrowth 8 Weeks after End of N.J. (August 13th, 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE MKT: SNT) announced today the results from th
Read more →-ELOX
Jul 30, 2012Senesco's Lead Therapeutic Candidate, SNS01-T, Granted Orphan Drug Status from FDA for Treatment of Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma BRIDGEWATER, N.J. (July 30 th , 2012) - Senesco Tec
Lead Therapeutic Candidate, SNS01-T, Granted Orphan Drug Status from FDA for Treatment of Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma BRIDGEWATER, N.J. (July 30th, 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE MKT: SNT) reported today that i
Read more →-ELOX
Jun 4, 2012Senesco Provides SNS01-T Update on Phase 1b/2a Multiple Myeloma Trial BRIDGEWATER, N.J. (June 4 th , 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE MKT: SNT) reported today on the progress of its P
Senesco Provides SNS01-T Update on Phase 1b/2a Multiple Myeloma Trial BRIDGEWATER, N.J. (June 4th, 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE MKT: SNT) reported today on the progress of its Phase 1b/2a study for the treatment of multiple myeloma, wh
Read more →-ELOX
May 15, 2012Senesco Technologies Reports Fiscal 2012 Third Quarter Results BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today reported financial results
Senesco Technologies Reports Fiscal 2012 Third Quarter Results BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today reported financial results for the third quarter of fiscal year 2012 which ended on March 31, 201
Read more →-ELOX
May 1, 2012Combination of Lenalidomide and SNS01-T Effective in Cancer Model Tumors Eliminated in Over 80% of Animals Treated with Optimal Dose BRIDGEWATER, N.J. (May 1 st , 2012) - Senesco Technologies, Inc. ("Senesco" or the "Com
Combination of Lenalidomide and SNS01-T Effective in Cancer Model Tumors Eliminated in Over 80% of Animals Treated with Optimal Dose BRIDGEWATER, N.J. (May 1st, 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE AMEX: SNT) announced today that a high leve
Read more →-ELOX
Mar 7, 2012Senesco Adds Additional Clinical Site to Evaluate SNS01-T in Multiple Myeloma BRIDGEWATER, N.J. (March 7 th , 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE AMEX: SNT) today announced that it has r
Senesco Adds Additional Clinical Site to Evaluate SNS01-T in Multiple Myeloma BRIDGEWATER, N.J. (March 7th, 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE AMEX: SNT) today announced that it has received Institutional Review Board approval and has finali
Read more →-ELOX
Mar 2, 2012Senesco Announces Additional $1.0 Million Equity Financing Follow-on to January 2012 Financing BRIDGEWATER, N.J. (March 2nd, 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE AMEX: SNT) announced toda
Senesco Announces Additional $1.0 Million Follow-on to January 2012 Financing BRIDGEWATER, N.J. (March 2nd, 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE AMEX: SNT) announced today that it has entered into a securities purchase agreement to raise an ad
Read more →-ELOX
Mar 1, 2012Senesco Adds Second Clinical Site to Evaluate SNS01-T in Multiple Myeloma BRIDGEWATER, N.J. (March 1 st , 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE AMEX: SNT) today announced that it has recei
Senesco Adds Second Clinical Site to Evaluate SNS01-T in Multiple Myeloma BRIDGEWATER, N.J. (March 1st, 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE AMEX: SNT) today announced that it has received Institutional Review Board approval and has finalized
Read more →-ELOX
Feb 15, 2012Senesco Technologies Reports Second Quarter Fiscal 2012 Financial Results BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today reported financi
Senesco Technologies Reports Second Quarter Fiscal 2012 Financial Results BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today reported financial results for the second quarter of fiscal year 2012 which ended on D
Read more →-ELOX
Feb 14, 2012BioCorp Ventures and Senesco Enter into License Agreement for the Application of eIF5A to Sustainable Energy Companies will cooperate to commercialize cutting-edge gene regulation technology for biofuels San Francisco, C
BioCorp Ventures and Senesco Enter into License Agreement for the Application of eIF5A to Sustainable Energy Companies will cooperate to commercialize cutting-edge gene regulation technology for biofuels San Francisco, Calif., and Bridgewater, N.J., February 14th, 2012 -BioCorp
Read more →-ELOX
Jan 11, 2012Senesco Announces $2.0 Million Equity Financing BRIDGEWATER, N.J. (January 9 th , 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE AMEX: SNT) announced today that it has entered into a securities pur
Senesco Announces $2.0 Million Equity Financing BRIDGEWATER, N.J. (January 9th, 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE AMEX: SNT) announced today that it has entered into a securities purchase agreement to raise approximately $2.0 million in gross
Read more →-ELOX
Jan 3, 2012Unassociated Document SNS01-T Demonstrates Synergy with Lenalidomide in Cancer Model Results at Biotech Showcase 2012 in San Francisco BRIDGEWATER, N.J. (January 3 rd , 2012) - Senesco Technologies, Inc. ("Senesco" or th
SNS01-T Demonstrates Synergy with Lenalidomide in Cancer Model Results at Biotech Showcase 2012 in San Francisco BRIDGEWATER, N.J. (January 3rd, 2012) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE AMEX: SNT) announced today that the combination of lenalidomide
Read more →-ELOX
Dec 27, 2011Unassociated Document Company Contact: Investor Relations Contact : Senesco Technologies, Inc. CEOcast, Inc. Leslie J. Browne, Ph.D. Robert Woods President and CEO ( rwoods@ceocast.com ) (908) 864-4444 (212) 732-4300 NYS
Company Contact: Investor Relations Contact : Senesco Technologies, Inc. CEOcast, Inc. Leslie J. Browne, Ph.D. Robert Woods President and CEO ( rwoods@ceocast.com ) (908) 864-4444 (212) 732-4300 NYSE AMEX ACCEPTS SENESCO TECHNOLOGIES' PLAN OF COMPLIANCE BRIDGEWATER, N.J. (Decem
Read more →-ELOX
Dec 1, 2011Unassociated Document Senesco Receives Milestone Payment from Bayer CropScience Bridgewater, N.J. (December 1 st , 2011) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE AMEX: SNT) announced today that Bay
Senesco Receives Milestone Payment from Bayer CropScience Bridgewater, N.J. (December 1st, 2011) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE AMEX: SNT) announced today that Bayer CropScience has made an undisclosed R&D milestone payment related to Bayer's use
Read more →-ELOX
Nov 15, 2011Senesco Technologies Reports First Quarter Fiscal 2012 Financial Results BRIDGEWATER, N.J.-(BUSINESS WIRE)- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today reported financial
Senesco Technologies Reports First Quarter Fiscal 2012 Financial Results BRIDGEWATER, N.J.-(BUSINESS WIRE)- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today reported financial results for the first quarter of fiscal year 2012 which ended on Septembe
Read more →-ELOX
Nov 3, 2011Unassociated Document Senesco Initiates Dosing in Phase 1b/2a Clinical Study of SNS01-T First in Human Study of eIF5A Modulation in Treatment of Disease BRIDGEWATER, N.J.--(
Senesco Initiates Dosing in Phase 1b/2a Clinical Study of SNS01-T First in Human Study of eIF5A Modulation in Treatment of Disease BRIDGEWATER, N.J.--(November 3, 2011)-- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced the initiation of
Read more →-ELOX
Oct 26, 2011Unassociated Document Senesco Technologies Provides Corporate Update BRIDGEWATER, N.J. (
Senesco Technologies Provides Corporate Update BRIDGEWATER, N.J. (October 26, 2011) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE AMEX: SNT) provided an update on Company activities. Clinical Trial Status Update Senesco has its first clinical trial of SNS01-T
Read more →-ELOX
Sep 29, 2011Senesco Technologies Reports Fiscal Year 2011 Financial Results BRIDGEWATER, N.J. (
Senesco Technologies Reports Fiscal Year 2011 Financial Results BRIDGEWATER, N.J. (September 29, 2011) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced financial results for the 12 months ended June 30, 2011 ("Fiscal 2011"). Fiscal Four
Read more →-ELOX
Aug 24, 2011Unassociated Document Senesco Finalizes Agreement with Mayo Clinic to Study SNS01-T in Multiple Myeloma BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today
Senesco Finalizes Agreement with Mayo Clinic to Study SNS01-T in Multiple Myeloma BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced that it has finalized a clinical trial agreement with Mayo Clinic in Ro
Read more →-ELOX
Aug 8, 2011Unassociated Document Senesco Technologies Selects Criterium to Manage Multiple Myeloma Study BRIDGEWATER, N.J.(August 8 th , 2011)--(BUSINESS WIRE)-- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: S
Senesco Technologies Selects Criterium to Manage Multiple Myeloma Study BRIDGEWATER, N.J.(August 8th, 2011)--(BUSINESS WIRE)-- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced that it has contracted Criterium, Inc. to manage the operationa
Read more →-ELOX
Jun 20, 2011Unassociated Document Senesco Technologies Told By FDA It May Proceed - SNS01-T IND Is Open Bridgewater, N.J. (June 20 th , 2011) -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announce
Senesco Technologies Told By FDA It May Proceed - SNS01-T IND Is Open Bridgewater, N.J. (June 20th, 2011) -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced that the Company has been told by the U.S. Food and Drug Administration (the "FDA
Read more →-ELOX
May 16, 2011Senesco Technologies Reports Third Quarter Fiscal 2011 Financial Results NEW BRUNSWICK, N.J. (
Senesco Technologies Reports Third Quarter Fiscal 2011 Financial Results NEW BRUNSWICK, N.J. (May 16, 2011) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced financial results for the third quarter ended March 31, 2011. Fiscal Third Quar
Read more →-ELOX
Mar 10, 2011Unassociated Document Senesco's Lead Therapeutic Candidate SNS01-T Waiting for Update to Vendor's Drug Master File New Brunswick, N.J. (March 10 th , 2011) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE
Senesco's Lead Therapeutic Candidate SNS01-T Waiting for Update to Vendor's Drug Master File New Brunswick, N.J. (March 10th, 2011) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT), announced today that the U.S. Food and Drug Administration (the "FDA")
Read more →-ELOX
Feb 10, 2011Senesco Technologies Reports Second Quarter Fiscal 2011 Financial Results NEW BRUNSWICK, N.J.--(BUSINESS WIRE) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today reported finan
Technologies Reports Second Quarter Fiscal 2011 Financial Results BRUNSWICK, N.J.--(BUSINESS WIRE) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today reported financial results for the second quarter ended December 31, 2010. During the quarter, th
Read more →-ELOX
Jan 24, 2011Senesco Technologies Announces IND Filing With FDA For SNS01-T NEW BRUNSWICK, N.J. (
Technologies Announces IND Filing With FDA For SNS01-T BRUNSWICK, N.J. (January 24, 2011) -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced that the Company has filed an Investigational New Drug ("IND") application with the U.S. Food a
Read more →-ELOX
Jan 3, 2011Senesco Technologies' Lead Therapeutic Candidate SNS01-T Granted Orphan Drug Status from FDA for Treatment of Multiple Myeloma New Brunswick, N.J. (January 3 rd , 2011) - Senesco Technologies, Inc. ("Senesco" or the "Com
Technologies' Lead Therapeutic Candidate SNS01-T Granted Orphan Drug Status from FDA for Treatment of Multiple Myeloma New Brunswick, N.J. (January 3rd, 2011) - Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT), announced today that the U.S. Food and D
Read more →-ELOX
Nov 15, 2010: Senesco Technologies, Inc. Lippert/Heilshorn & Associates, Inc. Leslie J. Browne, Ph.D. Anne Marie Fields President & Chief Executive Officer afields@lhai.com (
Company Contact: Investor Relations Contact : Senesco Technologies, Inc. Lippert/Heilshorn & Associates, Inc. Leslie J. Browne, Ph.D. Anne Marie Fields President & Chief Executive Officer afields@lhai.com (732) 296-8400 (212) 838-3777 TECHNOLOGIES REPORTS FIRST QUARTER FISC
Read more →-ELOX
Nov 2, 2010Unassociated Document Company Contact: Investor Relations Contact: Senesco Technologies, Inc. Lippert/Heilshorn & Associates, Inc. Leslie J. Browne, Ph.D., Anne Marie Fields President & CEO ( afields@lhai.com ) (732) 296
Company Contact: Investor Relations Contact: Senesco Technologies, Inc. Lippert/Heilshorn & Associates, Inc. Leslie J. Browne, Ph.D., Anne Marie Fields President & CEO ( afields@lhai.com ) (732) 296-8400 (212) 838-3777 TECHNOLOGIES REGAINS NYSE AMEX LISTING COMPLIANCE NEW BRUNS
Read more →-ELOX
Sep 29, 2010Senesco Technologies, Inc. Lippert/Heilshorn & Associates, Inc. Leslie J. Browne, Ph.D. Anne Marie Fields President & Chief Executive Officer afields@lhai.com (7
Company Contact: Investor Relations Contact: Senesco Technologies, Inc. Lippert/Heilshorn & Associates, Inc. Leslie J. Browne, Ph.D. Anne Marie Fields President & Chief Executive Officer afields@lhai.com (732) 296-8400 (212) 838-3777 TECHNOLOGIES REPORTS FISCAL YEAR 2010 FINANCI
Read more →-ELOX
May 24, 2010Unassociated Document Company Contact: Investor Relations Contact : Senesco Technologies, Inc. Lippert/Heilshorn & Associates, Inc. Jack Van Hulst Anne Marie Fields Chief Executive Officer ( afields@lhai.com ) ( jvanhuls
Company Contact: Investor Relations Contact : Senesco Technologies, Inc. Lippert/Heilshorn & Associates, Inc. Jack Van Hulst Anne Marie Fields Chief Executive Officer ( afields@lhai.com ) ( jvanhulst@senesco.com ) (212) 838-3777 (732) 296-8400 NAMES BIOPHARMACEUTICAL EXEC
Read more →-ELOX
May 18, 2010DRAFT #1 MAY 12, 2010 Company Contact: Investor Relations Contact: Senesco Technologies, Inc. Lippert/Heilshorn & Associates, Inc. Jack Van Hulst Anne Marie Fields Chief Executive Officer (afields@lhai.com) (jvanhulst@se
Company Contact: Investor Relations Contact: Senesco Technologies, Inc. Lippert/Heilshorn & Associates, Inc. Jack Van Hulst Anne Marie Fields Chief Executive Officer (afields@lhai.com) (jvanhulst@senesco.com) (212) 838-3777 (732) 296-8400 TECHNOLOGIES REPORTS FISCAL THIRD QUART
Read more →-ELOX
May 5, 2010DRAFT 1 Company Contact: Investor Relations Contact: Senesco Technologies, Inc. Lippert/Heilshorn & Associates, Inc. Jack Van Hulst Anne Marie Fields Chief Executive Officer ( afields@lhai.com ) (jvanhulst@senesco.com) (
Company Contact: Investor Relations Contact: Senesco Technologies, Inc. Lippert/Heilshorn & Associates, Inc. Jack Van Hulst Anne Marie Fields Chief Executive Officer ( afields@lhai.com ) (jvanhulst@senesco.com) (212) 838-3777 (732) 296-8400 TECHNOLOGIES REPORTS NYSE AMEX RESCIN
Read more →-ELOX
Apr 8, 2010Senesco Technologies, Inc. FD Jack Van Hulst Brian Ritchie Chief Executive Officer (brian.ritchie@fd.com) (jvanhulst@senesco.com) (212) 850-5683 (732) 296-8400 SENESCO TECHNOL
Company Contact: Investor Relations Contact: Senesco Technologies, Inc. FD Jack Van Hulst Brian Ritchie Chief Executive Officer (brian.ritchie@fd.com) (jvanhulst@senesco.com) (212) 850-5683 (732) 296-8400 TECHNOLOGIES RECEIVES NOTICE OF NON COMPLIANCE FROM NYSE AMEX NEW BRUNSW
Read more →-ELOX
Apr 5, 2010Unassociated Document Company Contact: Investor Relations Contact: Senesco Technologies, Inc. FD Joel Brooks Brian Ritchie Chief Financial Officer (brian.ritchie@fd.com) ( jbrooks@senesco.com ) (212) 850-5600 (732) 296-8
Company Contact: Investor Relations Contact: Senesco Technologies, Inc. FD Joel Brooks Brian Ritchie Chief Financial Officer (brian.ritchie@fd.com) ( jbrooks@senesco.com ) (212) 850-5600 (732) 296-8400 Technologies, Inc. Closes on Previously Announced Financing BRUNSWICK, N.J
Read more →-ELOX
Mar 29, 2010Unassociated Document Company Contact: Investor Relations Contact : Senesco Technologies, Inc. FD Joel Brooks Brian Ritchie Chief Financial Officer (brian.ritchie@fd.com) ( jbrooks@senesco.com ) (212) 850-5600 (732) 296-
Company Contact: Investor Relations Contact : Senesco Technologies, Inc. FD Joel Brooks Brian Ritchie Chief Financial Officer (brian.ritchie@fd.com) ( jbrooks@senesco.com ) (212) 850-5600 (732) 296-8400 Technologies, Inc. Announces Private Placement Financing for Gross t
Read more →-ELOX
Mar 5, 2010Senesco Technologies, Inc. FD Jack Van Hulst Brian Ritchie Chief Executive Officer (brian.ritchie@fd.com) (jvanhulst@senesco.com) (212) 850-5600 (732) 296-8400
Company Contact: Investor Relations Contact: Senesco Technologies, Inc. FD Jack Van Hulst Brian Ritchie Chief Executive Officer (brian.ritchie@fd.com) (jvanhulst@senesco.com) (212) 850-5600 (732) 296-8400 INSIDERS ELECT CONVERSION PRICE FAVORABLE TO RELATED TO SECURITIES PREVI
Read more →-ELOX
Feb 22, 2010Unassociated Document Company Contact: Investor Relations Contact : Senesco Technologies, Inc. FD Jack Van Hulst Brian Ritchie Chief Executive Officer ( brian.ritchie@fd.com ) ( jvanhulst@senesco.com ) (212) 850-5600 (73
Company Contact: Investor Relations Contact : Senesco Technologies, Inc. FD Jack Van Hulst Brian Ritchie Chief Executive Officer ( brian.ritchie@fd.com ) ( jvanhulst@senesco.com ) (212) 850-5600 (732) 296-8400 SENESCO INSIDERS PURCHASE SENESCO SECURITIES HELD STANFORD VENTURE
Read more →-ELOX
Feb 17, 2010: Senesco Technologies, Inc. FD Joel Brooks Brian Ritchie Chief Financial Officer brian.ritchie@fd.com jbrooks@senesco.com 212-850-5600 (732) 296-8400 Senesco Tec
Company Contact: Investor Relations Contact : Senesco Technologies, Inc. FD Joel Brooks Brian Ritchie Chief Financial Officer brian.ritchie@fd.com jbrooks@senesco.com 212-850-5600 (732) 296-8400 Technologies Reports Second Quarter Fiscal 2010 Financial Results BRUNSWICK, N.J.
Read more →-ELOX
Feb 4, 2010Senesco Technologies, Inc. FD Jack Van Hulst Brian Ritchie President and Chief Executive Officer (brian.ritchie@fd.com) (jvanhulst@senesco.com) (212) 850-5600 (732) 296-8400 S
Company Contact: Investor Relations Contact: Senesco Technologies, Inc. FD Jack Van Hulst Brian Ritchie President and Chief Executive Officer (brian.ritchie@fd.com) (jvanhulst@senesco.com) (212) 850-5600 (732) 296-8400 TECHNOLOGIES, INC. ANNOUNCES MANAGEMENT CHANGE BRUNSWICK,
Read more →-ELOX
Jan 19, 2010Unassociated Document Company Contact: Investor Relations Contact: Senesco Technologies, Inc. FD Joel Brooks Brian Ritchie Chief Financial Officer (brian.ritchie@fd.com) (jbrooks@senesco.com) (212) 850-5683 (732) 296-840
Company Contact: Investor Relations Contact: Senesco Technologies, Inc. FD Joel Brooks Brian Ritchie Chief Financial Officer (brian.ritchie@fd.com) (jbrooks@senesco.com) (212) 850-5683 (732) 296-8400 AMEX ACCEPTS SENESCO TECHNOLOGIES' PLAN OF COMPLIANCE NEW BRUNSWICK, N.J. (Ja
Read more →-ELOX
Nov 17, 2009: Investor Relations Contact : Senesco Technologies, Inc. FD Joel Brooks Brian Ritchie Chief Financial Officer brian.ritchie@fd.com jbrooks@senesco.com 212-850-5600 (732) 296-8400 Senesco Te
Company Contact : Investor Relations Contact : Senesco Technologies, Inc. FD Joel Brooks Brian Ritchie Chief Financial Officer brian.ritchie@fd.com jbrooks@senesco.com 212-850-5600 (732) 296-8400 Technologies Reports First Quarter Fiscal 2010 Financial Results BRUNSWICK,
Read more →-ELOX
Nov 16, 2009Senesco Technologies, Inc. FD Jack Van Hulst Brian Ritchie President and Chief Executive Officer ( brian.ritchie@fd.com ) ( jvanhulst@senesco.com ) (212) 850-5600 (732) 296-84
Company Contact: Investor Relations Contact: Senesco Technologies, Inc. FD Jack Van Hulst Brian Ritchie President and Chief Executive Officer ( brian.ritchie@fd.com ) ( jvanhulst@senesco.com ) (212) 850-5600 (732) 296-8400 TECHNOLOGIES, INC. ANNOUNCES BRUNSWICK, N.J. - Novembe
Read more →-ELOX
Nov 9, 2009Senesco Technologies, Inc. FD Bruce Galton Brian Ritchie Chief Executive Officer ( brian.ritchie@fd.com ) ( bgalton@senesco.com ) (212) 850-5600 (732) 296-8400
Company Contact: Investor Relations Contact: Senesco Technologies, Inc. FD Bruce Galton Brian Ritchie Chief Executive Officer ( brian.ritchie@fd.com ) ( bgalton@senesco.com ) (212) 850-5600 (732) 296-8400 SENESCO INSIDERS TO PURCHASE SENESCO SECURITIES HELD BY STANFORD VENTURE
Read more →-ELOX
Nov 4, 2009Senesco Technologies, Inc. FD Bruce Galton Brian Ritchie Chief Executive Officer (brian.ritchie@fd.com) (bgalton@senesco.com) (212) 850-5683 (732) 296-8400 SENESCO TECHNOLOGIE
Company Contact: Investor Relations Contact: Senesco Technologies, Inc. FD Bruce Galton Brian Ritchie Chief Executive Officer (brian.ritchie@fd.com) (bgalton@senesco.com) (212) 850-5683 (732) 296-8400 TECHNOLOGIES RECEIVES NOTICE OF NON COMPLIANCE FROM AMEX NEW BRUNSWICK, N.J.
Read more →-ELOX
Sep 29, 2009: Senesco Technologies, Inc. Joel Brooks Chief Financial Officer jbrooks@senesco.com (732) 296-8400 FD Brian Ritchie brian.ritchie@fd.com 212-850-5600 Senesco Tec
Company Contact: Investor Relations Contact : Senesco Technologies, Inc. Joel Brooks Chief Financial Officer jbrooks@senesco.com (732) 296-8400 FD Brian Ritchie brian.ritchie@fd.com 212-850-5600 Senesco Technologies Reports Fiscal Year 2009 Financial Results NEW BRUNSWICK, N.J.
Read more →-ELOX
Jul 29, 2009Media Relations Contact: Senesco Technologies, Inc. FD FD Joel Brooks Brian Ritchie Irma Gomez-Dib Chief Financial Officer brian.ritchie@fd.com irma.gomez-dib@fd.com jbrooks@s
Company Contact: Investor Relations Contact: Media Relations Contact: Senesco Technologies, Inc. FD FD Joel Brooks Brian Ritchie Irma Gomez-Dib Chief Financial Officer brian.ritchie@fd.com irma.gomez-dib@fd.com jbrooks@senesco.com (212) 850-5600 (212) 850-5600 (732) 296-8400 T
Read more →-ELOX
Jul 10, 2009ArborGen and Senesco Announce Wood Quality Results SUMMERVILLE, S.C., July 7 /PRNewswire/ -- ArborGen, LLC, a leader in forest tree improvement technologies, today announced wood quality results from ongoing field trials
and Senesco Announce Wood Quality Results S.C., July 7 /PRNewswire/ -- ArborGen, LLC, a leader in forest tree improvement technologies, today announced wood quality results from ongoing field trials that are utilizing technology in-licensed from Senesco Technologies, Inc. (NY
Read more →-ELOX
Jul 9, 2009: Senesco Technologies, Inc. FD Joel Brooks Brian Ritchie Chief Financial Officer (brian.ritchie@fd.com) ( jbrooks@senesco.com ) (212) 850-5600 (732) 296-8400 SENESCO TECHNOLOG
Company Contact: Investor Relations Contact : Senesco Technologies, Inc. FD Joel Brooks Brian Ritchie Chief Financial Officer (brian.ritchie@fd.com) ( jbrooks@senesco.com ) (212) 850-5600 (732) 296-8400 TECHNOLOGIES ENTERS INTO AGREEMENT FOR UP TO $1.0 MILLION IN BRUNSWICK, N.
Read more →-ELOX
Jun 9, 2009Media Relations: Senesco Technologies, Inc. FD FD Bruce Galton Brian Ritchie Irma Gomez-Dib Chief Executive Officer brian.ritchie@fd.com irma.gomez-dib@fd.com bgalton@senesco.
Company Contact: Investor Relations Contact: Media Relations: Senesco Technologies, Inc. FD FD Bruce Galton Brian Ritchie Irma Gomez-Dib Chief Executive Officer brian.ritchie@fd.com irma.gomez-dib@fd.com bgalton@senesco.com 212-850-5600 212-850-5600 (732) 296-8400 TECHNOLOGIES
Read more →-ELOX
May 26, 2009: Media Relations: Senesco Technologies, Inc. FD FD Bruce Galton Brian Ritchie Irma Gomez-Dib Chief Executive Officer brian.ritchie@fd.com irma.gomez-dib@fd.com bgalton@senesco
Company Contact: Investor Relations Contact : Media Relations: Senesco Technologies, Inc. FD FD Bruce Galton Brian Ritchie Irma Gomez-Dib Chief Executive Officer brian.ritchie@fd.com irma.gomez-dib@fd.com bgalton@senesco.com 212-850-5600 212-850-5600 (732) 296-8400 Announces H
Read more →-ELOX
May 4, 2009: Senesco Technologies, Inc. FD Joel Brooks Brian Ritchie Chief Financial Officer brian.ritchie@fd.com jbrooks@senesco.com 212-850-5600 (732) 296-8400 Senesco Technologies Repo
Company Contact: Investor Relations Contact : Senesco Technologies, Inc. FD Joel Brooks Brian Ritchie Chief Financial Officer brian.ritchie@fd.com jbrooks@senesco.com 212-850-5600 (732) 296-8400 Senesco Technologies Reports Third Quarter Fiscal 2009 NEW BRUNSWICK, N.J. (May 4,
Read more →-ELOX
Feb 3, 2009: Senesco Technologies, Inc. FD Bruce Galton Brian Ritchie Chief Executive Officer (brian.ritchie@fd.com) (bgalton@senesco.com) (212) 850-5600 (732) 296-8400 SENESCO ANNOUNCES
Company Contact: Investor Relations Contact : Senesco Technologies, Inc. FD Bruce Galton Brian Ritchie Chief Executive Officer (brian.ritchie@fd.com) (bgalton@senesco.com) (212) 850-5600 (732) 296-8400 SENESCO ANNOUNCES RESULTS OF PRE-CLINICAL TOXICOLOGY AND DOSE RANGING
Read more →Competitive Position
How ELOX ranks across every disease it competes inCompetitive Position is a premium feature
See how ELOX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial